Metastatic prostate cancer and the bone: Significance and therapeutic options

European Urology

Volumn 68, Issue 5, 2015, Pages 850-858

  Gartrell, Benjamin A ^a   Coleman, Robert ^b   Efstathiou, Eleni ^c,i   Fizazi, Karim ^d   Logothetis, Christopher J ^c   Smith, Matthew R ^e   Sonpavde, Guru ^f   Sartor, Oliver ^g   Saad, Fred ^h  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b WESTON PARK HOSPITAL   (United Kingdom)

^c David H Koch Center for Applied Research of Genitourinary Cancers   (United States)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f University of Alabama at Birmingham   (United States)

^g TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

ⁱ UNIVERSITY OF ATHENS   (Greece)

Author keywords

Bone metastases; Bone targeted agents; Prostate cancer; Skeletal related events; Symptomatic skeletal events

Indexed keywords

ANDROGEN AXIS TARGETED AGENT; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; DOCETAXEL; RADIUM CHLORIDE RA 223; UNCLASSIFIED DRUG; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; RADIOISOTOPE; RADIUM;

BONE MATRIX; BONE METASTASIS; BONE TURNOVER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; DISEASE COURSE; DNA DAMAGE; HUMAN; METASTATIC PROSTATE CANCER; OSTEOBLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SYSTEMATIC REVIEW; BONE NEOPLASMS; FRACTURES, SPONTANEOUS; MALE; METABOLISM; PATHOLOGY; PROSTATE TUMOR; SECONDARY;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DENOSUMAB; DIPHOSPHONATES; FRACTURES, SPONTANEOUS; HUMANS; IMIDAZOLES; MALE; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIUM;

EID: 84942986316     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.06.039     Document Type: Review

References (50)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J Clin 64 2014 9 29
2. D.C. Miller, K.S. Hafez, A. Stewart, J.E. Montie, and J.T. Wei Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base Cancer 98 2003 1169 1178
3. L. Bubendorf, A. Schopfer, U. Wagner, and et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients Hum Pathol 31 2000 578 583
4. M. Hussain, C.M. Tangen, D.L. Berry, and et al. Intermittent versus continuous androgen deprivation in prostate cancer N Engl J Med 368 2013 1314 1325
5. F. Saad, D.M. Gleason, R. Murray, and et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J Natl Cancer Inst 96 2004 879 882
6. K.P. Weinfurt, Y. Li, L.D. Castel, and et al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer Ann Oncol 16 2005 579 584
7. N. Sathiakumar, E. Delzell, M.A. Morrisey, and et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006 Prostate Cancer Prostatic Dis 14 2011 177 183
8. F. Saad, S. Segal, and J. Eastham Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid Eur Urol 65 2014 146 153
9. N.S. Tchekmedyian, Y.M. Chen, and F. Saad Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration-resistant prostate cancer, lung cancer, or other solid tumors Cancer Invest 28 2010 849 855
10. J.E. Brown, R.J. Cook, P. Major, and et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors J Natl Cancer Inst 97 2005 59 69
11. K. Fizazi, C. Massard, M. Smith, and et al. Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer Eur Urol 68 2015 42 50
12. L. Costa, L.M. Demers, A. Gouveia-Oliveira, and et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status J Clin Oncol 20 2002 850 856
13. M. Koizumi, J. Yonese, I. Fukui, and E. Ogata The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone BJU Int 87 2001 348 351
14. R.J. Cook, R. Coleman, J. Brown, and et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer Clin Cancer Res 12 2006 3361 3367
15. S. Rajpar, C. Massard, A. Laplanche, and et al. Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer Ann Oncol 21 2010 1864 1869
16. A. Lipton, R. Cook, F. Saad, and et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid Cancer 113 2008 193 201
17. S.L. Teitelbaum Bone resorption by osteoclasts Science 289 2000 1504 1508
18. W.C. Dougall, M. Glaccum, K. Charrier, and et al. RANK is essential for osteoclast and lymph node development Genes Dev 13 1999 2412 2424
19. Y.Y. Kong, H. Yoshida, I. Sarosi, and et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis Nature 397 1999 315 323
20. N. Bucay, I. Sarosi, C.R. Dunstan, and et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification Genes Dev 12 1998 1260 1268
21. S. Paget The distribution of secondary growths in cancer of the breast Cancer Metastasis Rev 8 1989 98 101
22. K.N. Weilbaecher, T.A. Guise, and L.K. McCauley Cancer to bone: a fatal attraction Nat Rev Cancer 11 2011 411 425
23. Y. Shiozawa, E.A. Pedersen, A.M. Havens, and et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow J Clin Invest 121 2011 1298 1312
24. T.A. Guise Molecular mechanisms of osteolytic bone metastases Cancer 88 2000 2892 2898
25. E.T. Keller, and J. Brown Prostate cancer bone metastases promote both osteolytic and osteoblastic activity J Cell Biochem 91 2004 718 729
26. K. Fizazi, M. Carducci, M. Smith, and et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Lancet 377 2011 813 822
27. C. Parker, S. Nilsson, D. Heinrich, and et al. Alpha emitter radium-223 and survival in metastatic prostate cancer N Engl J Med 369 2013 213 223
28. G. Henriksen, D.R. Fisher, J.C. Roeske, O.S. Bruland, and R.H. Larsen Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice J Nucl Med 44 2003 252 259
29. M.A. Ritter, J.E. Cleaver, and C.A. Tobias High-LET radiations induce a large proportion of non-rejoining DNA breaks Nature 266 1977 653 655
30. F. Saad, D.M. Gleason, R. Murray, and et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 2002 1458 1468
31. D.E. Rathkopf, M.R. Smith, J.S. de Bono, and et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302) Eur Urol 66 2014 815 825
32. S. Punnen, M.R. Cooperberg, A.V. D'Amico, and et al. Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature Eur Urol 64 2013 905 915
33. M.R. Smith, F. Kabbinavar, F. Saad, and et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer J Clin Oncol 23 2005 2918 2925
34. M. Wirth, T. Tammela, V. Cicalese, and et al. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS) Eur Urol 67 2015 482 491
35. M.R. Smith, F. Saad, R. Coleman, and et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial Lancet 379 2012 39 46
36. M.R. Smith, F. Saad, S. Oudard, and et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time J Clin Oncol 31 2013 3800 3806
37. S. Nilsson, A.O. Sartor, O.S. Bruland, F. Fang, A. Aksnes, and C. Parker Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases [abstract 19] J Clin Oncol 31. Suppl 6 2013
38. S. Nilsson, P. Strang, A.K. Aksnes, and et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer Eur J Cancer 48 2012 678 686
39. C.J. Ryan, M.R. Smith, J.S. de Bono, and et al. Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2013 138 148
40. F. Saad, K. Fizazi, M.R. Smith, and et al. Impact of concomitant bone-targeted therapies (BTT) on outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy (ctx) treated with abiraterone acetate (AA) or prednisone (P) [abstract 5037] J Clin Oncol 31 Suppl 2013
41. N.D. James, S. Pirrie, D. Barton, and et al. Clinical outcomes in patients with castrate-refractory prostate cancer (CRPC) metastatic to bone randomized in the factorial TRAPEZE trial to docetaxel (D) with strontium-89 (Sr89), zoledronic acid (ZA), neither, or both (ISRCTN 12808747) [abstract LBA5000] J Clin Oncol 31 Suppl 2013
42. J.J. Body, A. Lipton, J. Gralow, and et al. Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure J Bone Miner Res 25 2010 440 446
43. K. Fizazi, L. Bosserman, G. Gao, T. Skacel, and R. Markus Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial J Urol 182 2009 509 515 discussion 515-6
44. K. Fizazi, A. Lipton, X. Mariette, and et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates J Clin Oncol 27 2009 1564 1571
45. M.R. Smith, S. Halabi, C.J. Ryan, and et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (Alliance) J Clin Oncol 32 2014 1143 1150
46. O. Sartor, R. Coleman, S. Nilsson, and et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial Lancet Oncol 15 2014 738 746
47. P. Hoskin, A.O. Sartor, J.M. O'Sullivan, and et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial Lancet Oncol 15 2014 1397 1406
48. A.O. Sartor, R.E. Coleman, S. Nilsson, and et al. Safety of cytotoxic chemotherapy following radium-223 chloride (RA-223) therapy in the phase 3 ALSYMPCA study in patients with castration-resistant prostate cancer (CRPC) with bone metastases [abstract 936P] Ann Oncol 23 Suppl 9 2012
49. M.J. Morris, H.J. Hammers, C. Sweeney, and et al. Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): a phase I Prostate Cancer Clinical Trials Consortium study [abstract 5021] J Clin Oncol 31 Suppl 2013
50. M.J. Morris, C. Higano, H.I. Scher, and et al. Safety of radium-223 dichloride (Ra) with docetaxel (D) in patients (pts) with bone metastases (mets) from castration-resistant prostate cancer (CRPC): a phase 1/2a clinical trial [abstract 765PD] Ann Oncol 25 Suppl 4 2014